Oncology

Latest News

Within 5 years, the risk of SCC in particular was heightened among patients with MMP. | Image credit: wavebreak3 - stock.adobe.com

Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers

By AJMC Contributor

April 21st 2025

The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.

AI technology | Image: Adobe Stock

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

IVBM Atlanta | Image credit: AJMC

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

AJMC

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 24th 2016

Geographical Disparities Exist With US Smoking Prevention Policies

Surabhi Dangi-Garimella, PhD

Analysis by researchers from the American Cancer Society has found that US southern states rank at the top when it comes to death from cigarette smoking.

This Week in Managed Care: October 21, 2016

October 21st 2016

This Week in Managed Care: October 21, 2016

The top stories in managed care included Vice President Joe Biden's released his report on the Cancer Moonshot initiative, complaints were filed against 7 insurers for discriminating against people with HIV, and Pfizer announced it plans to launch its Remicade biosimilar in November.

October 21st 2016

5 Approaches for Improved Collaboration in Oncology Care

Surabhi Dangi-Garimella, PhD

Communication gaps complicate healthcare and can devastate the prognosis of a patient undergoing cancer treatment. Here are a few ways to overcome inconsistencies with cancer care delivery

October 20th 2016

Obesity: A Growing Burden for Cancer Survivors

Patients with a history of cancer were more likely to suffer from obesity than the general population, according to new research studying the incidence of obesity in cancer survivors.

October 20th 2016

NCHS Report: Rising Survivorship in Pediatric Cancers, Brain Cancer Leading Cause of Death

Surabhi Dangi-Garimella, PhD

Brain cancer has replaced leukemia as the leading cause of cancer-related death in children and adolescents diagnosed with cancer.

October 20th 2016

Underutilization of Follow-up Imaging in Breast Cancer Survivors a Cause for Concern

Surabhi Dangi-Garimella, PhD

A study presented at the 2016 Annual Clinical Congress of the American College of Surgeons claims that one-third of women diagnosed with breast cancer do not receive their follow-up exam.

October 19th 2016

Study Recommends Nutritional Intervention for Survivors of Childhood Cancer

Surabhi Dangi-Garimella, PhD

Diets lacking essential nutrients can exacerbate chronic conditions in survivors of childhood cancer and dietary interventions might be necessary to reduce morbidities in this population.

October 19th 2016

Bach, Califf Elected to National Academy of Medicine

Seventy Americans and 9 international members were elected to the National Academy of Medicine this week.

October 19th 2016

First PD-L1 Inhibitor Approved as Second-Line Treatment for NSCLC

Surabhi Dangi-Garimella, PhD

Atezolizumab, an inhibitor of the programmed death ligand-1 protein, has been approved for the treatment of patients with non-small cell lung cancer who failed to respond to treatment with platinum-based chemotherapy.

October 18th 2016

Minding the Gaps and Filling the Chasms in Oncology

Joseph Alvarnas, MD

As we enter a time of extraordinary advances in cancer care, some of the optimism over these advances has been temÂpered by the growing realization of the challenges of delivering these cancer care solutions.

October 17th 2016

Vice President Biden Delivers Cancer Moonshot Report to the Nation

Surabhi Dangi-Garimella, PhD

Vice President Joe Biden today presented the Cancer Moonshot report to President Barack Obama and the nation, delineating an actionable plan to transform cancer research and care delivery.

October 17th 2016

Enhancing Healthcare Delivery Research at the National Cancer Institute

Ann M. Geiger, MPH, PhD Ashley W. Smith, PhD, MPH Sarah C. Kobrin, PhD, MPH Stephen H. Taplin, MD

The National Cancer Institute's Division of Cancer Control and Population Sciences created the Healthcare Delivery Research Program in January 2015, recognizing the need for empirical evidence to address cancer care challenges.

October 14th 2016

Breast Cancer Death Rates Drop, but Racial Disparities Linger

Christina Mattina

Data released by the CDC today indicate that while breast cancer deaths are on the decline, black women still have worse outcomes than white women. The report also noted disparate trends in breast cancer incidence among different races and age groups.

This Week in Managed Care: October 14, 2016

October 14th 2016

This Week in Managed Care: October 14, 2016

This week, the top stories in managed care included HHS releasing the final rule for the Medicare Access and CHIP Reauthorization Act, a commentary on the downside of drug coupons, and the World Health Organization called on countries to enact a soda tax.

October 12th 2016

Radiomics to Predict Response to Antiangiogenic Therapy in Glioblastoma

Surabhi Dangi-Garimella, PhD

Radiomic combines imaging and computational technologies and can identify patients with recurrent glioblastoma who may benefit from using angiogenesis inhibitors.

October 12th 2016

Compassionate Use: FDA Is on Board, but Are Drug Manufacturers?

Surabhi Dangi-Garimella, PhD

A survey by Avalere Health found that only 19% of drug makers publicly post policies about their compassionate use programs.

October 12th 2016

What We're Reading: Limiting Use of Fentanyl, the Drug Fueling the Opioid Epidemic

What we're reading, October 12, 2016: a US senator calls for a limit to prescription fentanyl; healthcare costs aren't skyrocketing, despite claims; IBM's Watson will identify cancer treatment and clinical trials for IBM employees.

October 11th 2016

Reducing the Cost of Breast Cancer Treatment by $1 Billion

Surabhi Dangi-Garimella, PhD

A retrospective study in breast cancer patients suggests that patients can lower their out-of-pocket costs by speaking with their oncologist about alternate treatments that may be equally effective and understanding the drug coverage policy of their insurance plan.

October 11th 2016

Why You Should Attend Patient-Centered Oncology Care in Baltimore

Innovation in oncology treatments has reduced the mortality rate for cancer, but it comes at a price. At the 5th Annual Patient-Centered Oncology Care, experts will discuss cost-sharing models, as well as updates in cancer care treatment, such as precision medicine and immuno-oncology.

October 10th 2016

COST: A New Tool to Measure Financial Toxicity as a PRO

Surabhi Dangi-Garimella, PhD

Researchers at the University of Chicago have developed a clinically relevant patient-centered tool that can measure a patient’s risk for financial stress.

October 10th 2016

Estimating the Social Value of G-CSF Therapies in the United States

Jacqueline Vanderpuye-Orgle, PhD Alison Sexton Ward, PhD Caroline Huber, MPH Chelsey Kamson, BS Anupam B. Jena, MD, PhD

Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of febrile neutropenia in patients with cancer. This study evaluates the clinical and nonclinical value associated with G-CSFs.

October 10th 2016

Nivolumab Disappoints, Pembrolizumab May Replace Chemotherapy in Advanced NSCLC

Surabhi Dangi-Garimella, PhD

While nivolumab failed to surpass the outcomes of chemotherapy as first-line treatment in programmed death ligand-1—expressing patients with non-small cell lung cancer (NSCLC), pembrolizumab bettered chemotherapy in improving survival in a similar cohort.

October 7th 2016

Tamoxifen and AI Can Reduce Long-Term Risk of Contralateral Breast Cancer

Surabhi Dangi-Garimella, PhD

A retrospective analysis has found that longer term adjuvant treatment with tamoxifen significantly decreases the risk of contralateral breast cancer.

This Week in Managed Care: October 7, 2016

October 7th 2016

This Week in Managed Care: October 7, 2016

This week, the top managed care stories included conference coverage from the Academy of Managed Care Pharmacy's 2016 Nexus, Bill Clinton courted controversy when discussing the Affordable Care Act, and research finds fear of a job loss can increase the risk of diabetes.

October 7th 2016

Will HHS Have the Assurance of a Patient Identifier?

Surabhi Dangi-Garimella, PhD

HHS has been banned from using a patient identifier but several organizations, including national payers, providers, and prescription drug networks, want this reversed.

October 6th 2016

State-Level Insurance Reform Improved Access for Patients With CRC in Massachusetts

Surabhi Dangi-Garimella, PhD

A study published in the Journal of Clinical Oncology found an increased rate of resection and a reduction in the probability of emergent resection for colorectal cancer (CRC) as a result of insurance expansion in Massachusetts.

October 5th 2016

COA Report Accentuates Economic Strain on Community Practices

Surabhi Dangi-Garimella, PhD

According to the 2016 Community Oncology Practice Impact Report, about 15 community practices in the United States have either closed or were acquired, each month since 2008.

October 5th 2016

Following Nivolumab, NICE Rejects Pembrolizumab for Use in Patients With NSCLC

Surabhi Dangi-Garimella, PhD

A draft guidance issued by the National Institute for Health and Care Excellence (NICE) rejected use of Merck's programmed death-1 inhibitor pembrolizumab (Keytruda) in patients diagnosed with non-small cell lung cancer (NSCLC).

October 4th 2016

The Power of an Immuno-oncology Collaborative Care Team

Surabhi Dangi-Garimella, PhD

At the Institute for Clinical Immuno-Oncology National Conference, a panel of care providers presented institutional experiences with immunotherapy, and how a collaborative care approach helped the process.

October 4th 2016

PanCAN's Precision Medicine Trial Designed for Collaboration and Personalized Care

Surabhi Dangi-Garimella, PhD

Precision Promise, the Pancreatic Cancer Action Network (PanCAN)'s precision medicine trial, seeks to transform outcomes for pancreatic cancer patients with the goal set to double survival by 2020.

...

88 89 90 91 92 93 94 95 96

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions